scholarly journals Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study

2018 ◽  
Vol 6 ◽  
pp. 205031211877395 ◽  
Author(s):  
Md Rabiul Islam ◽  
Md Reazul Islam ◽  
Imtiaz Ahmed ◽  
Abdullah Al Moktadir ◽  
Zabun Nahar ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Elevated Serum ◽  
Area Under The Curve ◽  
Serum Levels ◽  
Significant Negative Correlation ◽  
Diagnostic Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
Characteristic Analysis ◽  
Major Depressive

Objectives: Major depressive disorder is diagnosed on the basis of patient’s self-reported experiences, behavior reported by relatives, and a mental status examination, and yet we do not have any reliable biomarker for this. Mood-regulating pathways are affected by oxidative injury to lipids and cortisol is released into the blood due to stimulation of corticotrophin receptors in the adrenal cortex. Here, we aimed to determine serum levels of malondialdehyde and cortisol in major depressive disorder patients and controls. Methods: We collected blood samples from 247 major depressive disorder patients and 248 controls. Serum levels of malondialdehyde and cortisol were measured by ultraviolet spectrophotometry and enzyme-linked immunosorbent assay kit, respectively. Results: We found malondialdehyde levels were significantly higher in patients than controls, with mean ± standard deviation at 4.49 ± 1.37 and 2.87 ± 0.82 µmol/L, respectively, p < 0.001. Cortisol levels were also found significantly higher in patients than controls, with mean ± SD at 19.22 ± 1.64 and 17.37 ± 1.34 µg/dL, respectively, p < 0.001. Significant negative correlation was observed between serum levels of malondialdehyde and cortisol in patients ( r =−0.170, p = 0.021). Receiver operating characteristic analysis showed good diagnostic value for malondialdehyde and cortisol, with the area under the curve at 0.853 and 0.819, respectively. Conclusion: The present study suggests that increased serum levels of malondialdehyde and cortisol are strongly associated with major depressive disorder. We believe elevations of malondialdehyde and cortisol in serum level arise independently and they could serve as biomarkers for major depressive disorder.

scholarly journals Monocyte chemoattractant protein-1 levels are associated with major depressive disorder

2020 ◽  
Author(s):  
Maliha Afrin Proma ◽  
Sohel Daria ◽  
Salsabil Islam ◽  
Zabun Nahar ◽  
Sardar Mohammad Ashraful Islam ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Rating Scale ◽  
Area Under The Curve ◽  
Significant Negative Correlation ◽  
Characteristic Analysis ◽  
Major Depressive ◽  
Monocyte Chemoattractant Protein 1 ◽  
Monocyte Chemoattractant ◽  
Monocyte Chemoattractant Protein

AbstractMajor depressive disorder (MDD) is a distressing condition characterized by persistent low mood, loss of interest in daily activities. Many biological, psycho-social, and genetic factors are thought to be involved with depression. The present study aimed to investigate the serum levels of monocyte chemoattractant protein-1 (MCP-1) in MDD patients to explore its role in the development of depression. This case-control study recruited 114 MDD patients and 106 healthy controls (HCs) matched by age and gender. A specialized psychiatrist diagnosed the cases and evaluated the controls based on the diagnostic and statistical manual for mental disorders, 5th edition. The serum MCP-1 levels were quantified by commercially available enzyme-linked immune sorbent assay kits. The Hamilton depression rating scale (Ham-D) was applied to measure the severity of depression. We observed the decreased levels of serum MCP-1 in MDD patients compared to HCs. A significant negative correlation was obtained between serum MCP-1 levels and Ham-D scores. Also, female MDD patients with higher Ham-D scores exhibited lower serum MCP-1 levels. The receiver operating characteristic analysis demonstrated the good diagnostic value of MCP-1 with the area under the curve at 0.837. The depression-related alteration of serum MCP-1 may be more complicated than the current assumption and depends on the characteristics of the individual patients. Our study suggests that the serum MCP-1 levels might be involved in the pathophysiology and mechanism of MDD. The present findings, along with the diagnostic evaluation, might be used to assess the depression risk.

scholarly journals Monocyte chemoattractant protein-1 levels are associated with major depressive disorder

2022 ◽  
Vol 0 (0) ◽  
Author(s):  
Maliha Afrin Proma ◽  
Sohel Daria ◽  
Zabun Nahar ◽  
Sardar Mohammad Ashraful Islam ◽  
Mohiuddin Ahmed Bhuiyan ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Rating Scale ◽  
Area Under The Curve ◽  
Significant Negative Correlation ◽  
Characteristic Analysis ◽  
Major Depressive ◽  
Monocyte Chemoattractant Protein 1 ◽  
Monocyte Chemoattractant ◽  
Monocyte Chemoattractant Protein

Abstract Objectives Major depressive disorder (MDD) is a distressing condition characterized by persistent low mood, loss of interest in daily activities. Researchers consider several biological, psycho-social, and genetic factors are involved in depression. The present study aimed to investigate the serum levels of monocyte chemoattractant protein-1 (MCP-1) in MDD patients to explore its role in depression. Methods This case-control study recruited 114 MDD patients and 106 healthy controls (HCs) matched by age and gender. A specialized psychiatrist diagnosed the cases and evaluated the controls based on the diagnostic and statistical manual for mental disorders, 5th edition. We quantified serum MCP-1 levels using commercially available enzyme-linked immune sorbent assay kits. Also, we applied the Hamilton depression rating scale (Ham-D) to measure the severity of depression. Results We observed the decreased levels of serum MCP-1 in MDD patients compared to HCs. Also, we obtained a significant negative correlation between serum MCP-1 levels and Ham-D scores. Moreover, female MDD patients with higher Ham-D scores exhibited lower serum MCP-1 levels. The receiver operating characteristic analysis demonstrated the good diagnostic value of MCP-1 with the area under the curve at 0.837. Conclusions The depression-related alteration of serum MCP-1 may be more complicated than the current assumption and depends on the characteristics of the individual patients. Our study suggests that the serum MCP-1 levels might involve in the pathophysiology and mechanism of MDD. The present findings, along with the diagnostic evaluation, might be used to evaluate depressive patients.

scholarly journals Serum interferon-gamma level is associated with drug-naïve major depressive disorder

2020 ◽  
Vol 8 ◽  
pp. 205031212097416
Author(s):  
Sohel Daria ◽  
Maliha Afrin Proma ◽  
Mohammad Shahriar ◽  
Sardar Mohammad Ashraful Islam ◽  
Mohiuddin Ahmed Bhuiyan ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Major Depressive Disorder ◽  
Major Depression ◽  
Depressive Disorder ◽  
Serum Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Major Depressive ◽  
Early Risk ◽  
Ifn Γ

Objectives: Major depressive disorder is a leading heterogeneous psychiatric illness manifested by persistent low mood, a feeling of sadness, and diminished interest in daily activities. Many biological, genetic, and social factors are thought to be linked with depression. But any suitable early risk assessment markers are absent for this illness. Therefore, we aimed to investigate the serum levels of IFN-γ in major depressive disorder patients to further investigate the association between serum levels of this cytokine and major depression. Methods: This prospective case-control study enrolled 120 major depressive disorder patients and 100 healthy controls matched by age, sex, and body mass index. A qualified psychiatrist diagnosed the major depressive disorder patients and evaluated healthy controls according to the Diagnostic and Statistical Manual of Mental Health Disorders (5th ed.; DSM-5). The Hamilton depression rating scale was applied for all the study participants to measure the severity of depression. Serum IFN-γ levels were measured by a commercially available enzyme-linked immunosorbent assay kit (Boster Biological Technology, Pleasanton, CA, USA). Results: This study observed that serum IFN-γ levels were significantly decreased in major depressive disorder patients compared to healthy controls. A significant negative correlation ( r = −0.375; p < 0.001) was obtained between serum IFN-γ levels and Hamilton depression scores. Receiver operating characteristic analysis showed good diagnostic performance of lowered serum IFN-γ levels in depression with an area under the curve at 0.790. Conclusion: We suggest the altered serum IFN-γ levels are associated with the pathophysiology of depression. The reduced levels of serum IFN-γ might be used as an early risk assessment tool for major depression.

scholarly journals Lysophosphatidic acid and lysophosphatidylcholine levels in serum samples of patients with major depressive disorder

2020 ◽  
Author(s):  
Sumaia Bari ◽  
Sharmin Sultana ◽  
Sohel Daria ◽  
Maliha Afrin Proma ◽  
Md. Rabiul Islam ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Lysophosphatidic Acid ◽  
Rating Scale ◽  
Serum Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Serum Samples ◽  
Major Depressive ◽  
Medical University

ABSTRACTMajor depressive disorder (MDD) is a heterogeneous condition featured with a continuous low mood, feeling of sadness, lack of interest to perform daily activities. Many factors including genetic, physiological, biological, social, and environmental are thought to be connected with the pathophysiology of depression. Several previous studies failed to identify the favorable biomarkers for MDD. Lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC)showed important roles in the regulation of emotion among experimental animals. The current study aimed to measure the serum levels of LPA and LPC in MDD patients and healthy controls (HCs) to explore their roles and relationship with depression. This case-control study enrolled 53 MDD patients and 50 healthy controls (HCs). The patients were recruited from the department of psychiatry, Bangabandhu Sheikh Mujib Medical University whereas the controls was from different locations of Dhaka city. Both the cases and controls were strictly matched by gender, age, and body mass index. A qualified psychiatrist diagnosed patients and evaluated controls based on the diagnostic and statistical manual of mental disorders, 5th edition. The severity of depression in MDD patients was measured by using the Hamilton depression rating scale (Ham-D). Enzyme-linked immunosorbent assay kits were used to measure serum levels LPA and LPC. We found no alterations of these parameters in serum levels of MDD patients compared to HCs. A significant positive correlation was found between serum LPA and LPC levels in MDD patients. Moreover, the present study showed no significant associations between target markers and either diagnosis of depression or Ham-D scores, or management of depression. The present study suggests that LPA and LPC levels probably would not serve as potential biomarkers of MDD. Thus, further studies with large and more homogeneous populations are recommended to explore the exact relationship between targeted serum lipids and major depression.

scholarly journals Higher levels of serum IL-1β and TNF-α are associated with an increased probability of major depressive disorder

2020 ◽  
Author(s):  
Rajesh Das ◽  
Md. Prova Zaman Emon ◽  
Mohammad Shahriar ◽  
Zabun Nahar ◽  
Sardar Mohammad Ashraful Islam ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Assessment Tools ◽  
Enzyme Linked Immunosorbent Assay ◽  
Characteristic Analysis ◽  
Major Depressive ◽  
Predictive Values ◽  
Tnf Α ◽  
Severity Of Depression

ABSTRACTMajor depressive disorder (MDD) is a serious psychiatric disorder but there are no reliable risk assessment tools for this condition. The actual reason for affecting depression is still controversial. It is assumed that the dysregulated cytokines are produced due to the hyperactivation of the immune system in depression. We aimed to evaluate the possible alteration and the role of serum interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in MDD patients. The diagnostic and statistical manual of mental disorders, 5th edition was used to diagnose patients and evaluation of healthy controls (HCs). The severity of depression was measured by the Hamilton depression rating scale (Ham-D). Serum IL-1β and TNF-α levels were quantified by enzyme-linked immunosorbent assay kits. Increased levels of serum IL-1β and TNF-α were observed in MDD patients compared to HCs. These higher levels of peripheral markers were positively correlated with the severity of depression. Moreover, females with higher Ham-D scores showed greater serum IL-1β and TNF-α levels compared to males. Good predictive values were detected for both serum IL-1β and TNF-α levels by receiver operating characteristic analysis. Therefore, the elevated levels of serum IL-1β and TNF-α might be used as risk assessment indicators for MDD.

scholarly journals High level of pattern glare in major depressive disorder

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Xiongwei Qi ◽  
Huanhuan Fan ◽  
Xiao Yang ◽  
Yayun Chen ◽  
Wei Deng ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cortical Excitability ◽  
Characteristic Curve ◽  
Significant Negative Correlation ◽  
Diagnostic Value ◽  
First Episode ◽  
Major Depressive ◽  
Control Subjects ◽  
Spatial Frequencies

Abstract Background Visual deficits have been reported in abundance by recent studies on major depressive disorder. Pattern glare manifests as visual distortions, such as the symptoms of headache, glare, eyestrain, illusions of shapes, colors, and motion when viewing repetitive striped patterns, of which some can be observed in major depressive disorder. Inspired by what mentioned, the present study aims to explore whether there exists association between pattern glare and major depressive disorder and further attempts to explore possible clinical diagnostic value of pattern glare in major depressive disorder. Methods Twenty-four patients diagnosed with major depressive disorder (MDDs group) were compared with 30 age-, gender- and education level-matched healthy control subjects (HCs group) on their visual stress with black-and-white gratings of different spatial frequencies-0.3 (low-SF), 2.3 (mid-SF), and 9.4 (high-SF) cycles per degree (c/deg)-which was named pattern glare test. The MDDs group divided into first episode medication-free group (fMDD) and recurrent medicated group (rMDD), comparisons of pattern glare scores (PGS) were performed within the MDDs group. We used Pearson and Spearman analysis to explore the relationship between some clinical indexes and pattern glare scores. ROC (receiver operating characteristic) curve was used to evaluate whether pattern glare test was able to discriminate patients and healthy controls. Results The mid-SF pattern glare score significantly elevated in patients with major depressive disorder compared to control subjects. No differences of pattern glare scores were found between fMDD and rMDD. A significant negative correlation between mid-high difference and age in HCs group was found. There were no correlations between other variables and pattern glare scores. The mid-SF score has limited value in the diagnosis of major depressive disorder. Conclusions We observed an increased level of pattern glare in patients with major depressive disorder, reflecting the existence of cortical hyper-excitability in major depressive disorder. The mid-SF score may have a value in understanding cortical excitability in major depressive disorder.

scholarly journals Relationship between spirituality and suicidal ideations among patients with major depressive disorder

2018 ◽  
Vol 9 (4) ◽  
pp. 113
Author(s):  
Souzan Abd El-Menem Abd El-Ghafar Harfus ◽  
Amal Awad Abd El-Nabi Moussa ◽  
Samar Mabrook El-Nehrawy
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Negative Correlation ◽  
Meaning In Life ◽  
Significant Negative Correlation ◽  
Structured Interview ◽  
Major Depressive ◽  
Correlational Design ◽  
Psychiatric Department ◽  
The Relationship

Background and objective: Suicide still constitutes to be a critical and risky issue requiring preventive strategies. There is evidence to suggest that spirituality is vital to the process of discovering meaning in life and plays an important role in dealing with suicidal desire. The aim of this study was to investigate the relationship between spirituality and suicidal ideations among patients with major depressive disorder.Methods: Design and participants: A descriptive correlational design was utilized in the current study. A purposive sample of 181 patients with major depressive disorder was recruited. Setting: The study was conducted at inpatient psychiatric department of Tanta University and Neurology, Psychiatry, and Neuro-Surgery Center. Both hospitals are under the supervision and direction of the ministry of higher education. Tools: Four tools were used to collect data; socio-demographic and clinical characteristics structured interview schedule, Beck Depression Inventory, Daily Spiritual Experience Scale, and Scale for Suicide Ideation.Results: The current study indicated a statistical significant negative correlation between depression and spirituality. Also, a statistical significant negative correlation was found between spirituality and one subscale of suicide which is active suicide desire subscale. On the other side, there was a statistical significant positive correlation between depression and total score of suicide.Conclusions: Higher levels of spirituality may help buffer risk of active suicide desire and promote protective effect against depression. Recommendation: interventions that aim at increasing spiritual involvement and practice may be beneficial in reducing depressive symptoms and suicide desire.

scholarly journals Association of serum uric acid levels with suicide risk in female patients with major depressive disorder: a comparative cross-sectional study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Jing-Xu Chen ◽  
Jun-Hui Feng ◽  
Li-Gang Zhang ◽  
Yan Liu ◽  
Fu-De Yang ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Uric Acid ◽  
Depressive Disorder ◽  
Suicide Risk ◽  
Serum Levels ◽  
Binary Logistic Regression Analysis ◽  
Healthy Controls ◽  
Major Depressive ◽  
Cross Sectional ◽  
Female Patients

Abstract Background Individuals with major depressive disorder (MDD) have a high suicide risk. Some evidence suggests that uric acid (UA) may be involved in the pathophysiology of MDD. The purpose of this study was to evaluate whether serum UA levels were associated with suicide risk in MDD patients. Methods One hundred four female patients with MDD (52 patients with suicide risk and 52 patients without suicide risk) and 52 healthy individuals were included in this study. The suicide risk was evaluated by Mini International Neuropsychiatric Interview (M.I.N.I.). Fasting serum levels of UA, as well as glucose, lipid and renal function indicators were measured. Results Serum UA levels in MDD patients with suicide risk (245.01 ± 55.44 μmol/L) were significantly lower than those in MDD patients without suicide risk (274.17 ± 72.65 μmol/L) (p = 0.017) and healthy controls (271.42 ± 55.25 μmol/L) (p = 0.030). There was no difference in serum UA levels between the MDD patients without suicide risk and healthy controls (p = 0.821). Binary logistic regression analysis revealed a significant relationship between suicide risk and decreased serum UA levels (OR = 0.989, p = 0.010) in MDD patients. Conclusion Decreased serum UA levels were associated with suicide risk in MDD patients. Purinergic system dysfunction may be involved in the neurobiological basis of suicide risk in these patients.

scholarly journals Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline—Results From a Randomized Controlled Clinical Trial

2021 ◽  
Vol 12 ◽  
Author(s):  
Maria S. Simon ◽  
Bianka Burger ◽  
Elif Weidinger ◽  
Gara Arteaga-Henríquez ◽  
Peter Zill ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Migration Inhibitory Factor ◽  
Macrophage Migration Inhibitory Factor ◽  
Inhibitory Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Depression Symptoms ◽  
Macrophage Migration ◽  
Major Depressive ◽  
Baseline Levels

Introduction: Previous research delivers strong indications that inflammatory activation leads to treatment resistance in a subgroup of patients with Major Depressive Disorder (MDD). Thus, tailored interventions are needed. The present study aimed to find potential biomarkers that may enable patients to be stratified according to immune activation.Methods: A phase IIa randomized placebo-controlled trial was performed to assess levels of inflammatory compounds in responders/remitters and non-responders/non-remitters to sertraline plus celecoxib (n = 20) and sertraline plus placebo (n = 23). Levels of macrophage migration inhibitory factor, neopterin, and tumor necrosis factor alpha were determined by enzyme-linked immunosorbent assay; response and remission were measured by reduction of the Montgomery Åsberg Depression Rating Scale score.Results: Both treatment groups showed a significant decline in depression symptoms, but no difference was found between groups. A clear pattern emerged only for macrophage migration inhibitory factor: placebo remitters showed significantly lower baseline levels than non-remitters (a similar trend was seen in responders and non-responders) while celecoxib responders showed a trend for higher baseline levels than non-responders.Conclusion: Small subsample sizes are a notable limitation, wherefore results are preliminary. However, the present study provides novel insights by suggesting macrophage migration inhibitory factor as a promising biomarker for treatment choice.The trial was registered in EU Clinical Trials Register (EU-CTR): https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011990-34/DE, EudraCT-No.: 2009-011990-34.

Sign in / Sign up

Export Citation Format

Share Document